Literature DB >> 6144819

Pulmonary infiltrates and eosinophilia associated with sulfasalazine.

K K Wang, B A Bowyer, C R Fleming, K W Schroeder.   

Abstract

Asymptomatic pulmonary infiltrates and eosinophilia developed in a patient with chronic ulcerative colitis 1 month after therapy with sulfasalazine had been instituted. The abnormalities resolved completely after use of the drug was discontinued. The sulfapyridine component of the sulfasalazine was the likely causative agent because 41 years earlier, the patient had experienced fever, myalgias, and eosinophilia after taking a sulfonamide. Ten previous cases of sulfasalazine pulmonary toxicity, including one fatality, have been reported.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6144819     DOI: 10.1016/s0025-6196(12)61431-1

Source DB:  PubMed          Journal:  Mayo Clin Proc        ISSN: 0025-6196            Impact factor:   7.616


  5 in total

Review 1.  Drug-induced respiratory disorders: incidence, prevention and management.

Authors:  L Ben-Noun
Journal:  Drug Saf       Date:  2000-08       Impact factor: 5.606

2.  Pneumonitis induced by sulphasalazine.

Authors:  F P Peters; L G Engels; A M Moers
Journal:  Postgrad Med J       Date:  1997-02       Impact factor: 2.401

3.  [Spectrum of hypereosinophilia syndrome based on 2 clinical case reports].

Authors:  H Nolte; U Helmchen
Journal:  Med Klin (Munich)       Date:  1998-07-15

4.  Reversible pulmonary disease and eosinophilia associated with sulphasalazine.

Authors:  A Jordan; R E Cowan
Journal:  J R Soc Med       Date:  1988-04       Impact factor: 18.000

Review 5.  HRCT Patterns of Drug-Induced Interstitial Lung Diseases: A Review.

Authors:  Giulio Distefano; Luigi Fanzone; Monica Palermo; Francesco Tiralongo; Salvatore Cosentino; Corrado Inì; Federica Galioto; Ada Vancheri; Sebastiano E Torrisi; Letizia A Mauro; Pietro V Foti; Carlo Vancheri; Stefano Palmucci; Antonio Basile
Journal:  Diagnostics (Basel)       Date:  2020-04-22
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.